Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Arcus Biosciences Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 366 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $24.42 |
|---|---|
| 52-week range | $16.74 - $49.10 |
| 50-day moving average | $22.99 |
| 200-day moving average | $32.69 |
| Wall St. target price | $57.20 |
| PE ratio | 33.5302 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.76 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $24.42 from 2022-06-28
| 1 week (2022-06-23) | -2.24% |
|---|---|
| 1 month (2022-05-26) | 34.18% |
| 3 months (2022-03-30) | -26.89% |
| 6 months (2021-12-29) | -42.11% |
| 1 year (2021-06-30) | -11.07% |
|---|---|
| 2 years (2020-06-30) | -1.29% |
| 3 years (2019-06-28) | 207.17% |
| 5 years (2017-06-26) | N/A |
Valuing Arcus Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arcus Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arcus Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Arcus Biosciences shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Arcus Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $64.3 million.
The EBITDA is a measure of a Arcus Biosciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $391.4 million |
|---|---|
| Operating margin TTM | 15.28% |
| Gross profit TTM | $126.5 million |
| Return on assets TTM | 3.02% |
| Return on equity TTM | 7.86% |
| Profit margin | 14.67% |
| Book value | $11.12 |
| Market capitalisation | $1.8 billion |
TTM: trailing 12 months
We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $16.74 up to $49.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.0115. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L. P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.